2-氯-5-异丙基吡啶 | 1204483-99-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氯-5-异丙基吡啶
• 英文名称: 2-Chloro-5-isopropoxypyridine
• 英文别名: 2-chloro-5-propan-2-yloxypyridine
• CAS: 1204483-99-7
• 化学式: C₈H₁₀ClNO
• 分子量: 171.62
• InChiKey: LXKKOEVIWJUAQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF
  申请人：EDWARDS John Simon

  公开号：US20170275327A1

  公开（公告）日：2017-09-28

  The present invention is directed to Compounds of Formula (I) and salts thereof, wherein R 1 , R 2 , R 3 and R 4 are defined above herein. The present invention is also directed to uses of the compounds of Formula (I) to add phosphoramidate groups onto organic alcohols.

  本发明涉及化合物（I）及其盐，其中R1、R2、R3和R4的定义如上所述。本发明还涉及将化合物（I）用于将磷酰胺基酸基团添加到有机醇中的用途。
• HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF
  申请人：Zoller Gerhard

  公开号：US20110183998A1

  公开（公告）日：2011-07-28

  Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.

  杂环衍生物、其制备方法、包含这些化合物的药物和其用途。本发明涉及式I中的化合物，其中基团R1、R2、R3、R4、W、A、B、D、E、G、L、M、R、T和Y具有所述的含义，并且其生理上可耐受的盐。该化合物适用于例如代谢综合征、胰岛素抵抗、肥胖和糖尿病的治疗。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20130289013A1

  公开（公告）日：2013-10-31

  Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.

  本发明公开了咪唑并[1,2-a]吡啶类化合物。本发明的化合物是有用的治疗剂，公开了它们在制药配方中的包含以及在治疗方法中的使用。
• Cyclic Sulfonamides as Sodium Channel Blockers
  申请人：PURDUE PHARMA L.P.

  公开号：US20150336974A1

  公开（公告）日：2015-11-26

  The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3a , R 3b , and n are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. For example, compounds of the present disclosure are useful for treating pain.
• US8470841B2
  申请人：——

  公开号：US8470841B2

  公开（公告）日：2013-06-25